VYNDAQEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VYNDAQEL (VYNDAQEL).
Tafamidis is a transthyretin (TTR) stabilizer that binds to TTR, inhibiting the dissociation of the TTR tetramer into monomers, which is the rate-limiting step in the formation of amyloid fibrils. By stabilizing the tetramer, it reduces amyloid deposition in tissues.
| Metabolism | Tafamidis is metabolized via glucuronidation by UGT1A1, UGT1A3, UGT1A4, and UGT2B7. Minor metabolism via CYP3A4 oxidation. Excreted primarily in feces (59%) and urine (22%). |
| Excretion | Primarily excreted unchanged in feces (approximately 70%) via biliary secretion; renal excretion is negligible (<1% of dose). |
| Half-life | Terminal elimination half-life is approximately 25 hours, supporting once-daily dosing with steady-state achieved by 2 weeks. |
| Protein binding | Highly bound (>99%) primarily to albumin, with minor binding to lipoproteins. |
| Volume of Distribution | Approximately 18 L (0.26 L/kg for a 70 kg individual), indicating distribution mainly into plasma and extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 100% (highly absorbed with minimal first-pass metabolism). |
| Onset of Action | Oral: Clinical effects on transthyretin stabilization occur within 2 weeks; maximal reduction in tetramer dissociation by 4 weeks. |
| Duration of Action | Duration of action persists for the dosing interval (24 hours) with sustained transthyretin stabilization; clinical benefits continuous with regular dosing. |
61 mg orally once daily
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²) or dialysis. |
| Liver impairment | No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Not studied in severe (Child-Pugh C) hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended. Clinical studies included patients aged 65 and older; no overall differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VYNDAQEL (VYNDAQEL).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Because of potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose. |
| Teratogenic Risk | Animal studies show developmental toxicity including reduced fetal growth and malformations at exposures below human therapeutic levels. There are no adequate human studies in pregnant women. Risk cannot be excluded in first trimester; potential for fetal harm throughout pregnancy. |
■ FDA Black Box Warning
None.
| Serious Effects |
["None known."]
| Precautions | ["Monitor serum uric acid levels; tafamidis increases serum uric acid, which may require urate-lowering therapy.","Monitor for atrial fibrillation or flutter; cases reported in clinical trials.","Monitor for drug interactions with strong CYP3A4 inhibitors/inducers and NSAIDs."] |
Loading safety data…
| Fetal Monitoring |
| Monitor liver function tests (ALT, AST, bilirubin) periodically; thyroid function tests; and for signs of heart failure exacerbation or volume overload. Fetal ultrasound for growth if used during pregnancy. |
| Fertility Effects | Animal studies show reduced fertility and increased preimplantation loss at clinically relevant exposures. Human data are lacking. |